Schlam I - Search Results

1

Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx^® Digital Spatial Profiler.

Bergholtz H, Carter JM, Cesano A, Cheang MCU, Church SE, Divakar P, Fuhrman CA, Goel S, Gong J, Guerriero JL, Hoang ML, Hwang ES, Kuasne H, Lee J, Liang Y, Mittendorf EA, Perez J, Prat A, Pusztai L, Reeves JW, Riazalhosseini Y, Richer JK, Sahin Ö, Sato H, Schlam I, Sørlie T, Stover DG, Swain SM, Swarbrick A, Thompson EA, Tolaney SM, Warren SE, On Behalf Of The GeoMx Breast Cancer Consortium. Bergholtz H, et al. Among authors: schlam i. Cancers (Basel). 2021 Sep 4;13(17):4456. doi: 10.3390/cancers13174456. Cancers (Basel). 2021. PMID: 34503266 Free PMC article.

2

Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?

Schlam I, Tolaney SM. Schlam I, et al. Oncotarget. 2021 Apr 27;12(9):873-875. doi: 10.18632/oncotarget.27904. eCollection 2021 Apr 27. Oncotarget. 2021. PMID: 33953840 Free PMC article. No abstract available.

3

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now.

Schlam I, Swain SM. Schlam I, et al. NPJ Breast Cancer. 2021 May 20;7(1):56. doi: 10.1038/s41523-021-00265-1. NPJ Breast Cancer. 2021. PMID: 34016991 Free PMC article. Review.

4

The tumor immune microenvironment of primary and metastatic HER2- positive breast cancers utilizing gene expression and spatial proteomic profiling.

Schlam I, Church SE, Hether TD, Chaldekas K, Hudson BM, White AM, Maisonet E, Harris BT, Swain SM. Schlam I, et al. J Transl Med. 2021 Nov 27;19(1):480. doi: 10.1186/s12967-021-03113-9. J Transl Med. 2021. PMID: 34838031 Free PMC article.

5

Overcoming Resistance to HER2-Directed Therapies in Breast Cancer.

Schlam I, Tarantino P, Tolaney SM. Schlam I, et al. Cancers (Basel). 2022 Aug 18;14(16):3996. doi: 10.3390/cancers14163996. Cancers (Basel). 2022. PMID: 36010990 Free PMC article. Review.

6

Emerging Targeted Therapies for Early Breast Cancer.

Schlam I, Tarantino P, Morganti S, Lynce F, Trapani D, Mayer EL, Garrido-Castro AC, Waks A, Tolaney SM. Schlam I, et al. Drugs. 2022 Sep;82(14):1437-1451. doi: 10.1007/s40265-022-01781-5. Epub 2022 Oct 7. Drugs. 2022. PMID: 36207645 Review.

7

How I treat HER2-low advanced breast cancer.

Schlam I, Tolaney SM, Tarantino P. Schlam I, et al. Breast. 2023 Feb;67:116-123. doi: 10.1016/j.breast.2023.01.005. Epub 2023 Jan 12. Breast. 2023. PMID: 36669993 Free PMC article. Review.

8

The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer.

Schlam I, Tolaney SM, Tarantino P. Schlam I, et al. Expert Rev Anticancer Ther. 2024 Nov;24(11):1059-1066. doi: 10.1080/14737140.2023.2171993. Epub 2023 Sep 12. Expert Rev Anticancer Ther. 2024. PMID: 36691884 Review.

9

Potential and Pitfalls of Pharmacovigilance Databases in Oncology.

Schlam I, Ewer MS, Swain SM. Schlam I, et al. JACC CardioOncol. 2023 Feb 21;5(1):99-101. doi: 10.1016/j.jaccao.2022.12.003. eCollection 2023 Feb. JACC CardioOncol. 2023. PMID: 36875912 Free PMC article.

10

Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer.

Mittal A, Molto Valiente C, Tamimi F, Schlam I, Sammons S, Tolaney SM, Tarantino P. Mittal A, et al. Among authors: schlam i. Cancers (Basel). 2023 Mar 28;15(7):2015. doi: 10.3390/cancers15072015. Cancers (Basel). 2023. PMID: 37046675 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38 results

Search Page

Filters